NCT00446719View on ClinicalTrials.gov

Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Depression
Interventions
DRUG

Rellidep

2000 mg P.O. daily for 8 weeks

Trial Locations (1)

M5G 1X5

Mount Sinai Hospital, Toronto

All Listed Sponsors
lead

Mount Sinai Hospital, Canada

OTHER

NCT00446719 - Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder | Biotech Hunter | Biotech Hunter